TWI788763B

The present disclosure provides, for example, a compound represented by general formula (6) below or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of the compound or salt:wherein X1, X2, X3 and X4 are each independently -CR2= or -N=, R2 is, for example, a halog...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	HATTORI, KAZUO, WATANABE, FUMIO, TOMIZAWA, MASAKI, ISSHIKI, YOSHIAKI, KAWASAKI, KENICHI, AOKI, TOSHIHIRO, HADA, KIHITO, HYODO, IKUMI
Format:	Patent
Sprache:	chi
Schlagworte:	ACYCLIC OR CARBOCYCLIC COMPOUNDS CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	HATTORI, KAZUO WATANABE, FUMIO TOMIZAWA, MASAKI ISSHIKI, YOSHIAKI KAWASAKI, KENICHI AOKI, TOSHIHIRO HADA, KIHITO HYODO, IKUMI
description	The present disclosure provides, for example, a compound represented by general formula (6) below or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of the compound or salt:wherein X1, X2, X3 and X4 are each independently -CR2= or -N=, R2 is, for example, a halogen atom, R1 is, for example, -S(=O)2-NH-R8, R8 is, for example, a C1-6 alkyl group, R3 is, for example, a hydrogen atom, R5 is, for example, a halogen atom, R6 is, for example, a hydrogen atom, and R4 is, for example, a cyclopropyl group. The compounds, salts or solvates provided by the present disclosure exhibit high RAF/MEK complex-stabilizing activity and can be used for the treatment or prevention of cell proliferative disorders, particularly cancers.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_TWI788763BB</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>TWI788763BB</sourcerecordid><originalsourceid>FETCH-epo_espacenet_TWI788763BB3</originalsourceid><addsrcrecordid>eNrjZOAKCfc0t7AwNzN24mFgTUvMKU7lhdLcDApuriHOHrqpBfnxqcUFicmpeakl8QgNTsZEKAEAET8bpg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>TWI788763B</title><source>esp@cenet</source><creator>HATTORI, KAZUO ; WATANABE, FUMIO ; TOMIZAWA, MASAKI ; ISSHIKI, YOSHIAKI ; KAWASAKI, KENICHI ; AOKI, TOSHIHIRO ; HADA, KIHITO ; HYODO, IKUMI</creator><creatorcontrib>HATTORI, KAZUO ; WATANABE, FUMIO ; TOMIZAWA, MASAKI ; ISSHIKI, YOSHIAKI ; KAWASAKI, KENICHI ; AOKI, TOSHIHIRO ; HADA, KIHITO ; HYODO, IKUMI</creatorcontrib><description>The present disclosure provides, for example, a compound represented by general formula (6) below or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of the compound or salt:wherein X1, X2, X3 and X4 are each independently -CR2= or -N=, R2 is, for example, a halogen atom, R1 is, for example, -S(=O)2-NH-R8, R8 is, for example, a C1-6 alkyl group, R3 is, for example, a hydrogen atom, R5 is, for example, a halogen atom, R6 is, for example, a hydrogen atom, and R4 is, for example, a cyclopropyl group. The compounds, salts or solvates provided by the present disclosure exhibit high RAF/MEK complex-stabilizing activity and can be used for the treatment or prevention of cell proliferative disorders, particularly cancers.</description><language>chi</language><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS ; CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230101&DB=EPODOC&CC=TW&NR=I788763B$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230101&DB=EPODOC&CC=TW&NR=I788763B$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>HATTORI, KAZUO</creatorcontrib><creatorcontrib>WATANABE, FUMIO</creatorcontrib><creatorcontrib>TOMIZAWA, MASAKI</creatorcontrib><creatorcontrib>ISSHIKI, YOSHIAKI</creatorcontrib><creatorcontrib>KAWASAKI, KENICHI</creatorcontrib><creatorcontrib>AOKI, TOSHIHIRO</creatorcontrib><creatorcontrib>HADA, KIHITO</creatorcontrib><creatorcontrib>HYODO, IKUMI</creatorcontrib><title>TWI788763B</title><description>The present disclosure provides, for example, a compound represented by general formula (6) below or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of the compound or salt:wherein X1, X2, X3 and X4 are each independently -CR2= or -N=, R2 is, for example, a halogen atom, R1 is, for example, -S(=O)2-NH-R8, R8 is, for example, a C1-6 alkyl group, R3 is, for example, a hydrogen atom, R5 is, for example, a halogen atom, R6 is, for example, a hydrogen atom, and R4 is, for example, a cyclopropyl group. The compounds, salts or solvates provided by the present disclosure exhibit high RAF/MEK complex-stabilizing activity and can be used for the treatment or prevention of cell proliferative disorders, particularly cancers.</description><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS</subject><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZOAKCfc0t7AwNzN24mFgTUvMKU7lhdLcDApuriHOHrqpBfnxqcUFicmpeakl8QgNTsZEKAEAET8bpg</recordid><startdate>20230101</startdate><enddate>20230101</enddate><creator>HATTORI, KAZUO</creator><creator>WATANABE, FUMIO</creator><creator>TOMIZAWA, MASAKI</creator><creator>ISSHIKI, YOSHIAKI</creator><creator>KAWASAKI, KENICHI</creator><creator>AOKI, TOSHIHIRO</creator><creator>HADA, KIHITO</creator><creator>HYODO, IKUMI</creator><scope>EVB</scope></search><sort><creationdate>20230101</creationdate><title>TWI788763B</title><author>HATTORI, KAZUO ; WATANABE, FUMIO ; TOMIZAWA, MASAKI ; ISSHIKI, YOSHIAKI ; KAWASAKI, KENICHI ; AOKI, TOSHIHIRO ; HADA, KIHITO ; HYODO, IKUMI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_TWI788763BB3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi</language><creationdate>2023</creationdate><topic>ACYCLIC OR CARBOCYCLIC COMPOUNDS</topic><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>HATTORI, KAZUO</creatorcontrib><creatorcontrib>WATANABE, FUMIO</creatorcontrib><creatorcontrib>TOMIZAWA, MASAKI</creatorcontrib><creatorcontrib>ISSHIKI, YOSHIAKI</creatorcontrib><creatorcontrib>KAWASAKI, KENICHI</creatorcontrib><creatorcontrib>AOKI, TOSHIHIRO</creatorcontrib><creatorcontrib>HADA, KIHITO</creatorcontrib><creatorcontrib>HYODO, IKUMI</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>HATTORI, KAZUO</au><au>WATANABE, FUMIO</au><au>TOMIZAWA, MASAKI</au><au>ISSHIKI, YOSHIAKI</au><au>KAWASAKI, KENICHI</au><au>AOKI, TOSHIHIRO</au><au>HADA, KIHITO</au><au>HYODO, IKUMI</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>TWI788763B</title><date>2023-01-01</date><risdate>2023</risdate><abstract>The present disclosure provides, for example, a compound represented by general formula (6) below or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of the compound or salt:wherein X1, X2, X3 and X4 are each independently -CR2= or -N=, R2 is, for example, a halogen atom, R1 is, for example, -S(=O)2-NH-R8, R8 is, for example, a C1-6 alkyl group, R3 is, for example, a hydrogen atom, R5 is, for example, a halogen atom, R6 is, for example, a hydrogen atom, and R4 is, for example, a cyclopropyl group. The compounds, salts or solvates provided by the present disclosure exhibit high RAF/MEK complex-stabilizing activity and can be used for the treatment or prevention of cell proliferative disorders, particularly cancers.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	chi
recordid	cdi_epo_espacenet_TWI788763BB
source	esp@cenet
subjects	ACYCLIC OR CARBOCYCLIC COMPOUNDS CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title	TWI788763B
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T05%3A53%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=HATTORI,%20KAZUO&rft.date=2023-01-01&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ETWI788763BB%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true